个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system

| 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Shu Yamin[1] * ; Chen Jing[1] ; Ding Yiling[2] ; Zhang Qilin[3] ;
单位： [1]Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. [2]Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan. [3]Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
出处：
DOI： 10.3389/fimmu.2023.1169735
ISSN：

关键词： adverse event disproportionality FAERS pharmacovigilance risankizumab

摘要：
Risankizumab, a humanized IgG1 monoclonal antibody that selectively inhibits IL-23, is currently approved for the treatment of moderate-to-severe plaque psoriasis and Crohn's disease. The real-world safety study of risankizumab in a large- sample population is currently lacking. The aim of this study was to evaluate risankizumab-associated adverse events (AEs) and characterize the clinical priority through the data mining of the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).Disproportionality analyses were performed by calculating the reporting odds ratios (RORs), deemed significant when the lower limit of the 95% confidence interval was greater than 1, to quantify the signals of risankizumab-related AEs from the second quarter (Q2) of 2019 to 2022 Q3. Serious and non-serious cases were compared, and signals were prioritized using a rating scale.Risankizumab was recorded in 10,235 reports, with 161 AEs associated with significant disproportionality. Of note, 37 PTs in at least 30 cases were classified as unexpected AEs, which were uncovered in the drug label, such as myocardial infarction, cataract, pancreatitis, diabetes mellitus, stress, and nephrolithiasis. 74.68%, 25.32%, and 0% PTs were graded as weak, moderate, and strong clinical priorities, respectively. A total of 48 risankizumab-related AEs such as pneumonia, cerebrovascular accident, cataract, loss of consciousness, cardiac disorder, hepatic cirrhosis, and thrombosis, were more likely to be reported as serious AEs. The median TTO of moderate and weak signals related to risankizumab was 115 (IQR 16.75-305) and 124 (IQR 29-301) days, respectively. All of the disproportionality signals had early failure type features, indicating that risankizumab-associated AEs gradually decreased over time.Our study found potential new AE signals and provided valuable evidence for clinicians to mitigate the risk of risankizumab-associated AEs based on an extensive analysis of a large-scale postmarketing international safety database.Copyright © 2023 Shu, Chen, Ding and Zhang.

基金：
National Natural Science Foundation of China (No. 82104476).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类 | 2 区 医学
小类 | 2 区 免疫学
最新[2025]版：
大类 | 2 区 医学
小类 | 2 区 免疫学
JCR分区：
出版当年[2021]版：
Q1 IMMUNOLOGY
最新[2023]版：
Q1 IMMUNOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者：
第一作者单位： [1]Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
通讯作者：
推荐引用方式(GB/T 7714)：
Shu Yamin,Chen Jing,Ding Yiling,et al.Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system[J].FRONTIERS IN IMMUNOLOGY.2023,14:doi:10.3389/fimmu.2023.1169735.
APA：
Shu Yamin,Chen Jing,Ding Yiling&Zhang Qilin.(2023).Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system.FRONTIERS IN IMMUNOLOGY,14,
MLA：
Shu Yamin,et al."Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system".FRONTIERS IN IMMUNOLOGY 14.(2023)

相关文献

[1]A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS) [2]Post-marketing safety concerns with palbociclib: a disproportionality analysis of the FDA adverse event reporting system [3]Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system [4]Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System [5]A Real-World Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting System [6]A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data [7]A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib [8]A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib [9]Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system [10]A real-world disproportionality analysis of mepolizumab based on the FDA adverse event reporting system

资源点击量：426 今日访问量：0 总访问量：408 更新日期：2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有：重庆聚合科技有限公司 渝ICP备12007440号-3 地址：重庆市两江新区泰山大道西段8号坤恩国际商务中心16层（401121）